caprotec bioanalytics Adds Two Patents to its Patent Estate
caprotec bioanalytics GmbH announced that the Canadian Patent Office has granted two Canadian patents covering the Company’s Capture Compound mass spectrometry (CCMS) technology. CCMS offers a novel and direct way to investigate small molecule-protein interactions resulting in a significant functional reduction of proteome complexity.
Canadian Patent No. 2,513,549, entitled “Capture Compounds, Collections Thereof and Methods For Analyzing the Proteome and Complex Compositions” covers these applications. Equivalent patents have been issued in Australia (2004206856) and Singapore (200504446-6), have been allowed in India and are pending in all major countries. The Canadian Patent No. 2.453,434, entitled “Compounds and Methods for Analyzing the Proteome” describes Capture Compounds and methods to discover protein biomarkers for diagnostic applications. An equivalent patent has been issued in Japan (3935487) and has been allowed as a European Patent, and applications are pending in major countries.
According to the company, Capture Compounds enable the direct isolation and identification of selected proteins, including membrane proteins, out of any complex biological sample. Another application is the profiling of small molecule drug-protein interactions to discover or confirm protein drug targets and potential off-target proteins that cause side effects. This knowledge is used for lead optimizations and risk assessment of candidate drugs to make a decision of whether to enter the expensive clinical trial process. CCMS therefore will help to significantly reduce the attrition rate, dramatically influencing time and cost of drug development.
Most read news
Topics
Organizations
Other news from the department research and development
Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
See the theme worlds for related content
Topic World Mass Spectrometry
Mass spectrometry enables us to detect and identify molecules and reveal their structure. Whether in chemistry, biochemistry or forensics - mass spectrometry opens up unexpected insights into the composition of our world. Immerse yourself in the fascinating world of mass spectrometry!
Topic World Mass Spectrometry
Mass spectrometry enables us to detect and identify molecules and reveal their structure. Whether in chemistry, biochemistry or forensics - mass spectrometry opens up unexpected insights into the composition of our world. Immerse yourself in the fascinating world of mass spectrometry!
Last viewed contents
Memory insight may prove beneficial for those with brain damage
Accurate measurement of radioactive thoron possible at last - PTB develops first primary standard worldwide for calibration of thoron measuring instruments
Breakthrough technology to rapidly identify unknown molecules at scale - Start-up Isospec Analytics raises $1.9m
Indicator of early form of Parkinson’s in stool sample
Agilent Technologies Publishes Industry’s First Compendium to Test for Synthetic Marijuana Compounds
Neuronal Parkinson inclusions are different than expected - Study raises new questions about the etiology of Parkinson’s disease
World's first toxicology testing strategy without animal testing adopted by OECD - Success for long-standing collaboration between BASF and Givaudan to develop and validate alternative methods
X-TubeProcessor_Smart | Laboratory robots | HTI Automation
Watching Molecular Machines at Work